Controversies in glaucoma: current medical treatment and drug development
C Bucolo, C Bianca Maria Platania… - Current …, 2015 - ingentaconnect.com
Elevated eye pressure is the main risk factor for glaucoma; intraocular pressure rises when
the ratio between aqueous humor formation (inflow) and its outflow is unbalanced. Currently …
the ratio between aqueous humor formation (inflow) and its outflow is unbalanced. Currently …
Pharmacotherapies for glaucoma
CB Toris - Current molecular medicine, 2010 - ingentaconnect.com
Glaucoma is a group of progressive optic neuropathies in which the axons in the optic nerve
are injured, retinal ganglion cell numbers are reduced and vision is gradually and …
are injured, retinal ganglion cell numbers are reduced and vision is gradually and …
Emerging drugs for ocular hypertension
AJ Lee, I Goldberg - Expert opinion on emerging drugs, 2011 - Taylor & Francis
Introduction: Glaucoma is a prevalent ocular disease with characteristic optic disc and visual
field changes. Globally, it is the second most common cause of visual disability, and the …
field changes. Globally, it is the second most common cause of visual disability, and the …
New pharmacotherapy for the treatment of glaucoma
EM Schehlein, G Novack, AL Robin - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Glaucoma is the second leading cause of blindness in the world and current
pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of …
pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of …
Pharmacological management of ocular hypertension: current approaches and future prospective
Elevated eye pressure is the main risk factor for glaucoma, and intraocular pressure rises
when the balance between aqueous humor formation and outflow resistance is …
when the balance between aqueous humor formation and outflow resistance is …
Advances in the discovery of novel agents for the treatment of glaucoma
F Mincione, A Nocentini, CT Supuran - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction Glaucoma, a neuropathy characterized by increased intraocular pressure (IOP),
is the major cause of blindness worldwide and its treatment aims at reducing IOP. Areas …
is the major cause of blindness worldwide and its treatment aims at reducing IOP. Areas …
Current and emerging medical therapies in the treatment of glaucoma
A Bagnis, M Papadia, R Scotto… - Expert opinion on …, 2011 - Taylor & Francis
Introduction: Glaucoma is a disease of the eye in which the optic nerve and retinal ganglion
cells (RGCs) are injured, leading to the loss of the peripheral visual field and eventually to …
cells (RGCs) are injured, leading to the loss of the peripheral visual field and eventually to …
The latest drugs in development that reduce intraocular pressure in ocular hypertension and glaucoma
V Jayanetti, S Sandhu, JA Lusthaus - Journal of Experimental …, 2020 - Taylor & Francis
Glaucoma causes irreversible vision loss, with elevated intraocular pressure (IOP) being the
only known modifiable risk factor. There are a variety of medical and interventional options …
only known modifiable risk factor. There are a variety of medical and interventional options …
Discovery of novel inhibitors for the treatment of glaucoma
Introduction: Glaucoma is a neurodegenerative disease with heterogeneous causes that
result in retinal ganglionic cell (RGC) death. The discovery of ocular antihypertensives has …
result in retinal ganglionic cell (RGC) death. The discovery of ocular antihypertensives has …
Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma
JA Lusthaus, I Goldberg - Expert Opinion on Investigational Drugs, 2016 - Taylor & Francis
Introduction: Intraocular pressure (IOP) is the most significant modifiable risk factor to
prevent onset or progression of glaucoma. Glaucoma prevalence continues to increase …
prevent onset or progression of glaucoma. Glaucoma prevalence continues to increase …